U.S. Interactive Media and Services Stock News

NYSE:BKV
NYSE:BKVOil and Gas

The Bull Case For BKV (BKV) Could Change Following Profitability And Expanded Carbon Capture Partnership - Learn Why

In February 2026, BKV Corporation reported fourth-quarter 2025 results showing revenue rising to US$330.09 million and net income of US$70.38 million, marking a shift from a loss a year earlier alongside higher natural gas production. The company also advanced its integrated gas, power and carbon capture model, including a US$500 million carbon capture partnership and refreshed CCUS injection targets that deepen its low-carbon energy ambitions. We’ll now explore how BKV’s move to...
NYSE:CMC
NYSE:CMCMetals and Mining

Assessing Commercial Metals (CMC) Valuation As Earnings, Acquisitions And Margin Program Draw Focus

Commercial Metals (CMC) is drawing fresh attention as it heads into its fiscal Q2 2026 earnings release and webcasted conference call, following two recent concrete products acquisitions. See our latest analysis for Commercial Metals. Recent trading has cooled after a strong run, with a 1 day share price return of 2.15% decline and a 30 day share price return of 5.98% decline. However, the 1 year total shareholder return of 53.28% and 5 year total shareholder return of 173.11% point to...
NYSE:RSI
NYSE:RSIHospitality

Assessing Rush Street Interactive (RSI) Valuation After Strong 2025 Results And Optimistic 2026 Guidance

Rush Street Interactive (RSI) is back in focus after reporting fourth quarter and full year 2025 results, with higher sales and net income, and issuing 2026 revenue guidance that signals management confidence in the business. See our latest analysis for Rush Street Interactive. The latest earnings release and 2026 revenue guidance appear to have reinforced interest in Rush Street Interactive, with a 7 day share price return of 6.64% and 30 day share price return of 11.77%, while the 1 year...
NYSE:FE
NYSE:FEElectric Utilities

The Bull Case For FirstEnergy (FE) Could Change Following 2025 Results And New US$36B Grid Plan

FirstEnergy Corp. has reported its 2025 results, with revenue rising to US$15.09 billion and net income reaching US$1.02 billion, alongside modestly higher earnings per share from continuing operations. At the same time, the company unveiled its Energize365 program, a US$36 billion capital plan for 2026–2030 that heavily prioritizes transmission upgrades and grid resilience, aiming to support long-term value creation. Next, we'll examine how this expanded US$36 billion Energize365 investment...
NYSE:WTTR
NYSE:WTTREnergy Services

Select Water Solutions (WTTR) Is Up 7.4% After $175 Million Equity Raise For Water Infrastructure Expansion – Has The Bull Case Changed?

In February 2026, Select Water Solutions, Inc. completed a US$175.0 million follow-on offering of 13,725,491 Class A shares at US$12.75 each under a new universal shelf registration, adding to its previously authorized but unused 2024 buyback program and prior completed repurchases. The company has indicated that the fresh equity capital will support general corporate purposes, including expanding its water infrastructure portfolio, potential acquisitions, and possible debt reduction,...
NYSE:SILA
NYSE:SILAHealth Care REITs

How Investors Are Reacting To Sila Realty Trust (SILA) Softer Earnings And Steady US$0.40 Dividend

Sila Realty Trust, Inc. reported past fourth-quarter and full-year 2025 results showing higher revenue of US$50.7 million for the quarter and US$197.54 million for the year, but lower net income of US$5.02 million and US$33.12 million respectively, while funds from operations reached US$30.4 million in Q4 and US$120.9 million for 2025. Alongside these earnings, the board approved a US$0.40 per-share quarterly dividend and highlighted high occupancy, strong lease retention, and active...
NYSE:CTEV
NYSE:CTEVHealthcare Services

Claritev (CTEV) Is Down 42.1% After Launching $75 Million Buyback Amid Ongoing Losses - What's Changed

Claritev Corporation recently reported past fourth-quarter 2025 sales of US$246.55 million and a net loss of US$80.57 million, alongside full-year 2025 sales of US$965.41 million and a net loss of US$284.28 million, and announced a new share repurchase program of up to US$75 million running through 2030. While the company remains loss-making, the year-on-year reduction in losses and the commitment to buying back shares suggest management is focused on improving financial discipline and...
NasdaqGS:PRDO
NasdaqGS:PRDOConsumer Services

Assessing Perdoceo Education’s (PRDO) Valuation After Earnings Growth Guidance And Dividend Affirmation

Perdoceo Education (PRDO) drew fresh attention after reporting fourth quarter and full year 2025 earnings, issuing new 2026 guidance, and affirming its quarterly dividend, giving investors several data points to reassess the stock. See our latest analysis for Perdoceo Education. The recent earnings, 2026 guidance and dividend affirmation come after a period of steady share price strength, with a 90 day share price return of 19.83% and a 1 year total shareholder return of 32.10% supporting a...
NYSE:UCB
NYSE:UCBBanks

Assessing Whether United Community Banks (UCB) Still Looks Undervalued After Recent Share Price Weakness

Without a specific news announcement driving attention today, United Community Banks (UCB) still offers investors concrete data points to consider, including recent share performance, profitability metrics, and value-focused scores. See our latest analysis for United Community Banks. At a share price of $32.17, United Community Banks has seen a 6.56% 1 month share price decline, while its 90 day share price return of 3.91% and 1 year total shareholder return of 3.10% point to relatively...
NYSE:GKOS
NYSE:GKOSMedical Equipment

Glaukos (GKOS) Valuation Check As iDose Sales Momentum Meets Impairment Charge And Upbeat 2026 Outlook

Glaukos (GKOS) is back in focus after its fourth quarter 2025 report paired strong sales figures with a sizeable impairment charge, followed shortly by fresh 2026 sales guidance and a new ESOP related shelf registration. See our latest analysis for Glaukos. The recent impairment charge and ESOP related shelf registration come against a backdrop of steady share price gains, with a 90 day share price return of 13.28% and a very large 3 year total shareholder return of 139.03%. This suggests...
NasdaqGS:XERS
NasdaqGS:XERSPharmaceuticals

Xeris Biopharma Holdings (XERS) Is Down 7.4% After Suing to Block Recorlev Generics Until 2040

Xeris Biopharma recently filed a Hatch-Waxman patent infringement lawsuit in the US District Court for the District of New Jersey against Torrent Pharmaceuticals and Somerset Therapeutics, seeking to block generic versions of its Cushing’s syndrome therapy Recorlev until its patents expire in March 2040. This legal move highlights how central Recorlev’s intellectual property protection is to Xeris’s long-term product exclusivity and potential revenue longevity in its endocrine...
NYSE:SEE
NYSE:SEEPackaging

Assessing Sealed Air (SEE) Valuation As Shares Trade Near Recent Levels

Why Sealed Air is on investors’ radar today Sealed Air (SEE) is back in focus after recent trading left the shares around $41.88, prompting investors to reassess how its packaging business and current valuation line up with their expectations. See our latest analysis for Sealed Air. While the 1-day and 7-day share price returns are slightly negative, Sealed Air’s 1-year total shareholder return of 25.46% contrasts with weaker 3-year and modest 5-year total shareholder returns, which suggests...
NasdaqGM:EYPT
NasdaqGM:EYPTPharmaceuticals

Is EyePoint (EYPT) Recasting Its Ophthalmology Playbook With a Veteran Launch Executive at DURAVYU?

EyePoint, Inc. recently appointed Michael Campbell as Chief Commercial Officer, giving him responsibility for commercial strategy and launch preparation for DURAVYU, its Phase 3 retinal disease candidate. The hire brings in a leader who helped shape the commercial playbooks behind Lucentis, Xiidra, Beovu and Tyrvaya, directly relevant to DURAVYU’s target markets. We’ll now examine how adding a veteran ophthalmology launch executive to oversee DURAVYU’s commercialization may influence...
NYSE:EMR
NYSE:EMRElectrical

Emerson Electric (EMR) Valuation Check After Q1 2026 Beat And Raised EPS Outlook

Emerson Electric (EMR) is back on investors’ radar after its Q1 2026 earnings report and a higher full year EPS forecast, with management pointing to electrification and nearshoring as key demand drivers. See our latest analysis for Emerson Electric. The Q1 earnings beat and raised EPS guidance arrived after a strong run, with a 90 day share price return of 14.26% and a 1 year total shareholder return of 26.02%, suggesting momentum has been building over both shorter and longer periods. If...
NasdaqGS:OMCL
NasdaqGS:OMCLMedical Equipment

Should Omnicell’s Shift Toward Software and Services Require Action From Omnicell (OMCL) Investors?

Omnicell has recently accelerated its shift from hardware-focused sales toward software and services, including acquiring ANiGENT in October 2025 to broaden its drug diversion detection capabilities and recurring revenue base. This pivot toward subscription-like revenue streams is prompting investors to reassess Omnicell less as a traditional equipment maker and more as a healthcare IT provider, with different expectations for growth, risk and valuation. Next, we’ll examine how Omnicell’s...
NYSE:ENS
NYSE:ENSElectrical

What EnerSys (ENS)'s New Mid‑Cap Fund Backing and Buyback Focus Means For Shareholders

In Q4 2025, Harbor Capital Advisors' Mid Cap Value Fund disclosed that it had initiated a new position in EnerSys, citing improving operating margins, sales growth, strong cash flow, ongoing share buybacks, and regular dividend payments as key reasons for the investment. The fund also ranked EnerSys in the top 5% of its evaluation universe, highlighting how the company’s combination of operating momentum and capital returns screens well against a broad mid-cap peer group. Next, we’ll examine...
NasdaqGS:VLY
NasdaqGS:VLYBanks

A Look At Valley National Bancorp (VLY) Valuation After Inflation Jitters And Credit Risk Concerns

Valley National Bancorp (VLY) shares dropped 6.2% as hotter inflation data and growing credit risk worries pressured regional lenders, even though the bank confirmed regular dividends and a new share repurchase authorization. See our latest analysis for Valley National Bancorp. Despite the latest 5.7% one day share price decline to US$12.61, Valley National Bancorp’s 90 day share price return of 9.8% and 1 year total shareholder return of 34.0% suggest momentum has generally been positive...
NYSE:ACA
NYSE:ACAConstruction

Assessing Arcosa (ACA) Valuation After Recent Share Pullback And Conflicting Fair Value Signals

Arcosa (ACA) is back on investors’ radar after a recent share pullback over the past week and month, drawing attention to how its infrastructure focused business and current valuation metrics stack up today. See our latest analysis for Arcosa. The sharp 1 day share price decline of 15.7% and 7 day share price return of 14.9% sit against a 1 year total shareholder return of 28.42% and 5 year total shareholder return of 84.39%. This suggests recent momentum has cooled after a strong multi year...
NYSE:LADR
NYSE:LADRMortgage REITs

How Ladder’s New US$1.25 Billion Unsecured Facility And Term Loan At Ladder Capital (LADR) Has Changed Its Investment Story

In February 2026, Ladder Capital Corp. announced it had secured US$675 million in new unsecured capital commitments, expanding its unsecured revolving credit facility to US$1.25 billion and adding a US$275 million unsecured delayed draw term loan priced at 140 basis points over SOFR. This package of same-day liquidity at 125 basis points over SOFR and long-dated funding to 2030 materially strengthens Ladder’s funding flexibility and duration profile. Next, we’ll examine how this expanded...
NasdaqGS:REG
NasdaqGS:REGRetail REITs

Regency Centers Note Sale Sparks Fresh Questions On Debt And Valuation

Regency Centers completed a public offering of $450 million in senior unsecured notes due 2033. The issuance is intended to support balance sheet optimization and ongoing development activities. The company trades on the NasdaqGS under the ticker NasdaqGS:REG, with a current share price of $79.0. For investors watching NasdaqGS:REG, this $450 million notes offering is a fresh data point on how Regency Centers is managing its capital structure. The stock is at $79.0, with returns of 2.8%...
NasdaqGS:LPLA
NasdaqGS:LPLACapital Markets

A Look At LPL Financial Holdings (LPLA) Valuation After Recent Share Price Weakness

LPL Financial Holdings (LPLA) has drawn attention after a period of weaker share performance, with returns over the past month, past 3 months, and year all in negative territory, even though multi year total returns remain positive. See our latest analysis for LPL Financial Holdings. The recent 1 month share price return of a 17.59% decline and year to date share price return of a 16.94% decline point to fading near term momentum, even though the 5 year total shareholder return of 129.88%...
NYSE:OC
NYSE:OCBuilding

Owens Corning Losses Spur Questions On Earnings Recovery And Valuation

Owens Corning (NYSE:OC) reported a net loss for the fourth quarter, reversing net income from the same period a year earlier. The company also posted a full year net loss, a material deterioration compared with the prior year's profitability. Recent results came in below earnings expectations, highlighting weaker than anticipated financial performance. For investors watching NYSE:OC, this shift to losses comes with the stock recently closing at $122.07. Shares are down 8.0% over the past...
NYSE:BCC
NYSE:BCCTrade Distributors

Is Boise Cascade (BCC) Fairly Priced After Housing Demand Headlines And Recent Share Pullback

If you are wondering whether Boise Cascade's share price still reflects its real worth, looking at how the market has treated the stock over different time frames is a useful starting point. The stock last closed at US$82.74, with returns of 0.7% over 7 days, 3.0% over 30 days, 11.6% year to date, but a 19.3% decline over 1 year and longer term returns of 36.4% over 3 years and 107.2% over 5 years. Recent headlines around Boise Cascade have focused on its position as a major supplier of...
NasdaqGM:NTLA
NasdaqGM:NTLABiotechs

Intellia Trial Milestones Refocus Attention On Gene Editing Risk And Reward

FDA lifts clinical hold on Intellia Therapeutics' MAGNITUDE-2 ATTR amyloidosis trial, allowing global enrollment to resume with updated safety protocols. Intellia completes phase 3 enrollment ahead of schedule in the HAELO trial for lonvo-z, a one time gene editing therapy for hereditary angioedema. These steps advance Intellia Therapeutics' late stage pipeline and move its gene editing candidates closer to potential approval and commercialization. For investors watching Intellia...